Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.039 AUD | -7.14% | -4.88% | +77.27% |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Feb. 28 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.15M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.28M | Net income 2023 | -2M -1.28M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 708K | Net cash position 2023 | 401K 257K | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.35% |
1 day | -7.14% | ||
1 week | -4.88% | ||
1 month | +8.33% | ||
3 months | +69.57% | ||
6 months | +25.81% | ||
Current year | +77.27% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.039 | -7.14% | 510 000 |
24-04-18 | 0.042 | 0.00% | 162,538 |
24-04-17 | 0.042 | +2.44% | 448,918 |
24-04-12 | 0.041 | 0.00% | 21,841 |
24-04-11 | 0.041 | 0.00% | 55,179 |
Delayed Quote Australian S.E., April 18, 2024 at 10:26 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+77.27% | 4.54M | |
-1.82% | 41.35B | |
+42.38% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ANR Stock